Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04628871 · ClinicalTrials.gov registry record
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
A clinical trial of Hemophilia B and Mucopolysaccharidosis II, sponsored by Sangamo Therapeutics.
- Active
- Registry status
- 13
- Enrollment target
- 5
- Study locations
NCT04628871 is a study of Hemophilia B and Mucopolysaccharidosis II that is active but no longer recruiting, run by Sangamo Therapeutics. The registered enrollment target is 13 participants, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (86% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04628871, a study of Hemophilia B and Mucopolysaccharidosis II, is active but no longer recruiting, sponsored by Sangamo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
Conditions Studied
Interventions
- BIOLOGICAL SB-318
- BIOLOGICAL SB-913
- BIOLOGICAL SB-FIX
Study Locations (5)
California
- UCSF Benioff Children's Hospital Oakland - Oakland
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
New York
- New York University Grossman School of Medicine - New York
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-11-03 |
| Est. Completion | 2030-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04628871
The ClinicalTrials.gov registry entry for NCT04628871 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 96-participant average among 20 other Hemophilia B trials with a reported enrollment target (86% lower). The listed sponsor is Sangamo Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hemophilia B appearing as the primary indexed condition, and to 3 interventions - of which SB-318 is the first listed.
NCT04628871 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT04628871 about?
NCT04628871 is a clinical study titled "Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX". Long-term follow-up of subjects who received SB-318, SB-913, or SB-FIX in a previous trial and completed at least 52 weeks post-infusion follow-up in their primary protocol. Enrolled subjects will be followed for a total of up to 10 years following exposure to SB-318, SB-913, or SB-FIX.
What is the current status of trial NCT04628871?
This trial is currently active not recruiting. The enrollment target is 13 participants. The study started on 2020-11-03. Estimated completion is 2030-01-01.
What conditions does trial NCT04628871 study?
This clinical trial studies the following conditions: Hemophilia B, Mucopolysaccharidosis II, Mucopolysaccharidosis I.
What interventions are being tested in trial NCT04628871?
The interventions under investigation include: SB-318 (BIOLOGICAL), SB-913 (BIOLOGICAL), SB-FIX (BIOLOGICAL).
Who is sponsoring clinical trial NCT04628871?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04628871 being conducted?
This trial has 5 study locations across California, Illinois, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia B
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
RECRUITING · Phase 3
-
BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B
RECRUITING · Phase 1
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)
RECRUITING · Phase 3
-
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.